regulatory
HHS Announces Draft Peptide Compounding Policy: What Changes, and What Does Not
HHS has announced a draft enforcement-discretion policy for certain peptide bulk substances. Here is what the notice says about access, timing, and FDA approval.
What HHS Announced
On October 28, 2026, HHS filed a notice announcing a draft enforcement-discretion policy for certain peptide bulk drug substances used in Section 503A compounding. The policy is intended to operate while FDA develops permanent additions to the 503A bulks list through rulemaking.
Enforcement discretion means an agency describes circumstances in which it does not intend to take enforcement action. It is different from changing the law, adding a substance permanently to the bulks list, or approving a finished drug. The notice identifies state-licensed pharmacies, federal facilities, and licensed physicians within its stated scope.
Which Peptides Are Reported?
Reuters reports that the policy covers BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon—the six peptides recommended by the advisory committee in July.
The three-page notice itself does not enumerate the substances. It refers to Appendix A in a separate policy document. Exact chemical forms, administration routes, combinations, and conditions must be checked against that document; inclusion of a peptide name is not blanket coverage for every formulation.
Does Access Begin October 30?
October 30, 2026 is the scheduled Federal Register publication date. The notice calls the policy a draft and accepts written comments for two weeks after publication under Docket HHS-OASH-2026-0496.
The notice does not clearly establish when compounders can begin relying on the policy. Neither publication nor the close of comments should be treated as an automatic treatment launch date. An operative interim policy could provide a pathway before permanent rulemaking is complete, but implementation needs confirmation.
What This Does Not Change
Compounded drugs are not FDA-approved. The notice does not establish the safety, effectiveness, or quality of these products, and it does not substantiate claims about injury healing, weight loss, or longevity.
This is a 503A policy—not a general authorization for 503B outsourcing production, all peptides, or research-use-only sellers. The policy does not establish enforceable rights and is not binding on HHS or the public. HHS may revisit it if safety signals or product-quality issues arise.
What This Means for GobyPeptides Readers
This development is a reason to follow access updates, not a reason to assume a treatment is available. GobyMeds has not announced availability for these six peptides. They remain on our information and waitlist pathway.
Any future offering depends on the operative policy, applicable state requirements, qualified pharmacy supply, and clinician review. The October notice does not change the availability of other treatments shown separately on this site.
Sources
About the editorial team
GobyPeptides Editorial writes with a careful, source-grounded lens focused on research summaries, regulatory context, and lawful access pathways.
Keep reading
FDA Advisory Committee Votes to Recommend Six Peptides for Compounding
On July 23-24, 2026 the FDA’s Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A bulks list. Emideltide was not recommended.
FDA Announces July 2026 Advisory Committee for Peptide Review
Ahead of the vote, the FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026 to weigh seven peptides for the 503A bulks list. The committee ultimately recommended six of them.